Literature DB >> 15474908

Dopamine transporter density in schizophrenic subjects with and without tardive dyskinesia.

Karmen K Yoder1, Gary D Hutchins, Evan D Morris, Allison Brashear, Chunzi Wang, Anantha Shekhar.   

Abstract

Striatal dopamine transporter (DAT) binding potential (BP) was compared between schizophrenic subjects with and without tardive dyskinesia and controls. Although the groups were not statistically different in striatal BP, tardive subjects had apparently lower DAT density than non-tardive schizophrenic subjects. Significant and trend-level inverse correlations were found between DAT BP in the striatum, and especially the severity of negative symptom scores, but also cognitive, and depression/anxiety scores on the PANSS.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15474908     DOI: 10.1016/j.schres.2004.03.015

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  11 in total

1.  Striatal presynaptic dopamine in schizophrenia, Part I: meta-analysis of dopamine active transporter (DAT) density.

Authors:  Paolo Fusar-Poli; Andreas Meyer-Lindenberg
Journal:  Schizophr Bull       Date:  2012-01-26       Impact factor: 9.306

2.  Fine-mapping reveals novel alternative splicing of the dopamine transporter.

Authors:  Michael E Talkowski; Kathleen L McCann; Michael Chen; Lora McClain; Mikhil Bamne; Joel Wood; Kodavali V Chowdari; Annie Watson; Konasale M Prasad; George Kirov; Lyudmilla Georgieva; Draga Toncheva; Hader Mansour; David A Lewis; Michael Owen; Michael O'Donovan; Panagiotis Papasaikas; Patrick Sullivan; Douglas Ruderfer; Jeffrey K Yao; Sherry Leonard; Pramod Thomas; Fabio Miyajima; John Quinn; A Javier Lopez; Vishwajit L Nimgaonkar
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2010-10-18       Impact factor: 3.568

3.  Relations between movement disorders and psychopathology under predominantly atypical antipsychotic treatment in adolescent patients with schizophrenia.

Authors:  Stefan Gebhardt; Fabian Härtling; Markus Hanke; Frank M Theisen; Richard von Georgi; Phillip Grant; Markus Mittendorf; Matthias Martin; Christian Fleischhaker; Eberhard Schulz; Helmut Remschmidt
Journal:  Eur Child Adolesc Psychiatry       Date:  2007-09-14       Impact factor: 4.785

Review 4.  Pathway-Specific Dopamine Abnormalities in Schizophrenia.

Authors:  Jodi J Weinstein; Muhammad O Chohan; Mark Slifstein; Lawrence S Kegeles; Holly Moore; Anissa Abi-Dargham
Journal:  Biol Psychiatry       Date:  2016-03-31       Impact factor: 13.382

5.  The role of striatal dopamine D2/3 receptors in cognitive performance in drug-free patients with schizophrenia.

Authors:  Tanja Veselinović; Ingo Vernaleken; Hildegard Janouschek; Paul Cumming; Michael Paulzen; Felix M Mottaghy; Gerhard Gründer
Journal:  Psychopharmacology (Berl)       Date:  2018-05-01       Impact factor: 4.530

Review 6.  Clinical significance of pharmacogenomic studies in tardive dyskinesia associated with patients with psychiatric disorders.

Authors:  Florence Cf Chang; Victor Sc Fung
Journal:  Pharmgenomics Pers Med       Date:  2014-10-13

7.  Pharmacodynamic genetic polymorphisms affect adverse drug reactions of haloperidol in patients with alcohol-use disorder.

Authors:  Mikhail Sergeevich Zastrozhin; Vadim Markovich Brodyansky; Valentin Yurievich Skryabin; Elena Anatolievna Grishina; Dmitry Vladimirovich Ivashchenko; Kristina Anatolievna Ryzhikova; Ludmila Mikhaylovna Savchenko; Alexander Olegovich Kibitov; Evgeny Alekseevich Bryun; Dmitry Alekseevich Sychev
Journal:  Pharmgenomics Pers Med       Date:  2017-07-07

8.  Combination of In Vivo [123I]FP-CIT SPECT and Microdialysis Reveals an Antipsychotic Drug Haloperidol-induced Synaptic Dopamine Availability in the Rat Midbrain and Striatum.

Authors:  So Hyeon Park; Yoo Sung Song; Byung Seok Moon; Byung Chul Lee; Hyun Soo Park; Sang Eun Kim
Journal:  Exp Neurobiol       Date:  2019-10-31       Impact factor: 3.261

Review 9.  Cognitive Function and Monoamine Neurotransmission in Schizophrenia: Evidence From Positron Emission Tomography Studies.

Authors:  Harumasa Takano
Journal:  Front Psychiatry       Date:  2018-05-29       Impact factor: 4.157

Review 10.  Presynaptic dopaminergic function: implications for understanding treatment response in psychosis.

Authors:  I Bonoldi; O D Howes
Journal:  CNS Drugs       Date:  2014-07       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.